{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:58Z","timestamp":1786979938623,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Extramedullary disease (EMD), an aggressive form of multiple myeloma (MM), may require a multi-targeted treatment approach rather than standard MM therapies. While precise EMD treatment outcome estimates remain challenging given small clinical trial patient numbers, pooled estimates across studies may increase outcome precision. Meta-regression analyses used Bayesian multilevel, random-effects modeling of patients with and without EMD across nine historical clinical studies of standard treatment regimens, including daratumumab, for relapsed\/refractory multiple myeloma (RRMM) from 2013 to 2019. EMD was defined as soft tissue plasmacytomas noncontiguous with bone (\u201ctrue\u201d EMD). Adjustments were performed to account for differences in baseline age, number of prior lines of therapy (LOT), and International Staging System (ISS) stage. Outcomes included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). In patients with EMD (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009158) versus without EMD (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092706), pooled ORR (95% credible interval) was 20.7% (11.7\u201333.9) versus 66.2% (53.0\u201377.4) with an odds ratio of 0.13 (0.09\u20130.20), pooled median PFS was 6.3 (4.2\u20139.5) versus 12.9 (8.8\u201318.8) months with a hazard ratio of 1.95 (1.63\u20132.32), and pooled median OS was 21.0 (15.9\u201327.9) versus 39.0 (31.0\u201348.5) months with a hazard ratio of 1.87 (1.53\u20132.26). Poorer outcomes in patients with versus without EMD were consistent following adjustment for age, number of prior LOT, and ISS stage. These results in patients with RRMM treated with standard treatment regimens confirmed notably worse outcomes in patients with versus without EMD, emphasizing continued unmet clinical need in this patient population.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06705-3","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:21:42Z","timestamp":1764739302000},"page":"6263-6274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes in patients with relapsed\/refractory multiple myeloma with extramedullary disease: a meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Peter M.","family":"Voorhees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael C.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"6705_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosi\u00f1ol L, Usmani SZ, Zamagni E, Richardson P (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12:45. https:\/\/doi.org\/10.1038\/s41408-022-00643-3","journal-title":"Blood Cancer J"},{"issue":"6","key":"6705_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10585-024-10305-2","volume":"41","author":"MH Elbahoty","year":"2024","unstructured":"Elbahoty MH, Papineni B, Samant RS (2024) Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics. Clin Exp Metastasis 41(6):829\u2013842. https:\/\/doi.org\/10.1007\/s10585-024-10305-2","journal-title":"Clin Exp Metastasis"},{"issue":"28","key":"6705_CR3","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/jco.2011.34.9290","volume":"29","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29(28):3805\u20133812. https:\/\/doi.org\/10.1200\/jco.2011.34.9290","journal-title":"J Clin Oncol"},{"issue":"6","key":"6705_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/pas.0000000000001459","volume":"44","author":"Y Liu","year":"2020","unstructured":"Liu Y, Jelloul F, Zhang Y, Bhavsar T, Ho C, Rao M, Lewis NE, Cimera R, Baik J, Sigler A, Sen F, Yabe M, Roshal M, Landgren O, Dogan A, Xiao W (2020) Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol 44(6):838\u2013848. https:\/\/doi.org\/10.1097\/pas.0000000000001459","journal-title":"Am J Surg Pathol"},{"key":"6705_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.941437","volume":"12","author":"S Forster","year":"2022","unstructured":"Forster S, Radpour R (2022) Molecular impact of the tumor microenvironment on multiple myeloma dissemination and extramedullary disease. Front Oncol 12:941437. https:\/\/doi.org\/10.3389\/fonc.2022.941437","journal-title":"Front Oncol"},{"issue":"2","key":"6705_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21(2):325\u2013330. https:\/\/doi.org\/10.1093\/annonc\/mdp329","journal-title":"Ann Oncol"},{"issue":"1","key":"6705_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kr\u00f6ger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann H-H, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G (2013) Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 161(1):87\u201394. https:\/\/doi.org\/10.1111\/bjh.12223","journal-title":"Br J Haematol"},{"issue":"9","key":"6705_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00527-y","volume":"11","author":"R Bansal","year":"2021","unstructured":"Bansal R, Rakshit S, Kumar S (2021) Extramedullary disease in multiple myeloma. Blood Cancer J 11(9):161. https:\/\/doi.org\/10.1038\/s41408-021-00527-y","journal-title":"Blood Cancer J"},{"issue":"5","key":"6705_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548\u2013567. https:\/\/doi.org\/10.1002\/ajh.25791","journal-title":"Am J Hematol"},{"issue":"2","key":"6705_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH (2020) Multiple myeloma: available therapies and causes of drug resistance. Cancers (Basel) 12(2):407. https:\/\/doi.org\/10.3390\/cancers12020407","journal-title":"Cancers (Basel)"},{"key":"6705_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K (2019) Multiple myeloma: an overview of management. Palliat Care Soc Pract 13:1178224219868235. https:\/\/doi.org\/10.1177\/1178224219868235","journal-title":"Palliat Care Soc Pract"},{"issue":"1","key":"6705_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H (2016) Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 128(1):37\u201344. https:\/\/doi.org\/10.1182\/blood-2016-03-705210","journal-title":"Blood"},{"issue":"4","key":"6705_CR13","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/s1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E (2017) Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18(4):e206\u2013e217. https:\/\/doi.org\/10.1016\/s1470-2045(17)30189-4","journal-title":"Lancet Oncol"},{"issue":"3","key":"6705_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk N, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fern\u00e1ndez de Larrea C, Gahrton G, Gay F, H\u00e1jek R, Hungria V, Jurczyszyn A, Kr\u00f6ger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Blad\u00e9 J (2021) Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 194(3):496\u2013507. https:\/\/doi.org\/10.1111\/bjh.17338","journal-title":"Br J Haematol"},{"key":"6705_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101465","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Sun Z, Qu X (2022) Advances in the treatment of extramedullary disease in multiple myeloma. Transl Oncol 22:101465. https:\/\/doi.org\/10.1016\/j.tranon.2022.101465","journal-title":"Transl Oncol"},{"issue":"2","key":"6705_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99(2):360\u2013364. https:\/\/doi.org\/10.3324\/haematol.2013.094409","journal-title":"Haematologica"},{"issue":"1","key":"6705_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, Coriu D, Rosi\u00f1ol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Bali\u0107 LI, Kastritis E, Blad\u00e9 J, Dimopoulos MA (2020) A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 105(1):201\u2013208. https:\/\/doi.org\/10.3324\/haematol.2019.219295","journal-title":"Haematologica"},{"issue":"11","key":"6705_CR18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S (2023) Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388(11):1002\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2213614","journal-title":"N Engl J Med"},{"issue":"18","key":"6705_CR19","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380(18):1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"issue":"22","key":"6705_CR20","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1002\/cncr.33809","volume":"127","author":"S Lonial","year":"2021","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Sborov D, Suvannasankha A, Weisel K, Voorhees PM, Womersley L, Baron J, Piontek T, Lewis E, Opalinska J, Gupta I, Cohen AD (2021) Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 127(22):4198\u20134212. https:\/\/doi.org\/10.1002\/cncr.33809","journal-title":"Cancer"},{"issue":"7","key":"6705_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/jco.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Oriol A, Larocca A, Blad\u00e9 J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV (2021) Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol 39(7):757\u2013767. https:\/\/doi.org\/10.1200\/jco.20.02259","journal-title":"J Clin Oncol"},{"issue":"1","key":"6705_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","volume":"36","author":"T Jelinek","year":"2022","unstructured":"Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, Stork M, Pour L, Pavlicek P, Spicka I, Maisnar V, Radocha J, Simicek M, Hajek R (2022) Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia 36(1):288\u2013291. https:\/\/doi.org\/10.1038\/s41375-021-01343-w","journal-title":"Leukemia"},{"key":"6705_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720571","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, Yuan J, Wang X, Wang Y, Deng Q (2021) Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol 12:720571. https:\/\/doi.org\/10.3389\/fimmu.2021.720571","journal-title":"Front Immunol"},{"key":"6705_CR24","doi-asserted-by":"publisher","unstructured":"Moreau P, Mateos MV, Goldschmidt H, Garcia MEG, Besemer B, Perez MSG, Mohty M, Lindsey-Hill J, Kirkpatrick S, Delforge M, Angelucci E, Raimondo FD, Vij R, Doyle M, Gray K, Albrecht C, Strulev V, Haddad I, Koskinen S, Acciarri L, Buyze J, Weisel K (2025) Outcomes of patients with extramedullary disease in triple-class exposed relapsed\/refractory multiple myeloma from the pooled locommotion and momment studies.\u00a0Clin Lymphoma Myeloma Leuk\u00a0646\u2013655. https:\/\/doi.org\/10.1016\/j.clml.2025.03.014","DOI":"10.1016\/j.clml.2025.03.014"},{"issue":"12","key":"6705_CR25","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D\u2019Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J (2023) Multiple myeloma, version 2.2024, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(12):1281\u20131301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"6705_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.18654","volume":"200","author":"D Minakata","year":"2023","unstructured":"Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y (2023) Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol 200(6):694\u2013703. https:\/\/doi.org\/10.1111\/bjh.18654","journal-title":"Br J Haematol"},{"issue":"1","key":"6705_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ (2021) Ipdfromkm: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"6705_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02273-8","volume":"24","author":"JZ Zhang","year":"2024","unstructured":"Zhang JZ, Rios JD, Pechlivanoglou T, Yang A, Zhang Q, Deris D, Cromwell I, Pechlivanoglou P (2024) SurvdigitizeR: an algorithm for automated survival curve digitization. BMC Med Res Methodol 24(1):147. https:\/\/doi.org\/10.1186\/s12874-024-02273-8","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"6705_CR29","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos M-V, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau J-L, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"6705_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1201\/b16018","volume-title":"Bayesian data analysis, third edition. Part II: Fundamentals of bayesian data analysis","author":"A Gelman","year":"2013","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB (2013) Bayesian data analysis, third edition. Part II: Fundamentals of bayesian data analysis. Chapman and Hall\/CRC Texts in Statistical Science Series Press. CRC, Boca Raton, pp 139\u2013257"},{"key":"6705_CR31","doi-asserted-by":"publisher","unstructured":"Brilleman SL, Elci EM, Novik JB, Wolfe R (2020) Bayesian survival analysis using the rstanarm R Package. https:\/\/doi.org\/10.48550\/arXiv.2002.09633","DOI":"10.48550\/arXiv.2002.09633"},{"issue":"Suppl 1","key":"6705_CR32","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1182\/blood-2019-129038","volume":"134","author":"AJ Yee","year":"2019","unstructured":"Yee AJ, Huff CA, Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Moreau P, Dingli D, Cole CE, Lonial S, Dimopoulos MA, Richter JR, Vij R, Tuchman SA, Hoffman JE, Costa LJ, Parker TL, Vlummens P, Doyen C, Biran N, Siegel DS, Shah J, Picklesimer C, Saint-Martin J-R, Li L, Kauffman MG, Shacham S, Richardson PG, Jagannath S (2019) Response to therapy and the effectiveness of treatment with selinexor and dexamethasone in patients with penta-exposed triple-class refractory myeloma who had plasmacytomas. Blood 134(Suppl 1):3140\u20133140. https:\/\/doi.org\/10.1182\/blood-2019-129038","journal-title":"Blood"},{"key":"6705_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106948","volume":"122","author":"M Beksac","year":"2022","unstructured":"Beksac M, Spicka I, Hajek R, Bringhen S, Jelinek T, Martin T, Mikala G, Moreau P, Symeonidis A, Rawlings AM, van de Velde H, Richardson PG (2022) Evaluation of isatuximab in patients with soft-tissue plasmacytomas: an analysis from ICARIA-MM and IKEMA. Leuk Res 122:106948. https:\/\/doi.org\/10.1016\/j.leukres.2022.106948","journal-title":"Leuk Res"},{"key":"6705_CR34","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD (2021) Doing meta-analysis with R: a hands-on guide, 1st edn. Chapman & Hall\/CRC, Boca Raton, FL and London. https:\/\/doi.org\/10.1201\/9781003107347","edition":"1"},{"key":"6705_CR35","unstructured":"Kumar S, Usmani SZ, Ye JC, Cohen YC, Voorhees PM, Scott E, Carson RL, Heuck C, Gan R, Kane C, Caplan E, Kanakamedala H, Parekh T, Mateos M-V (2024) Outcomes of patients with extramedullary disease and relapsed or refractory multiple myeloma from historical clinical trials. Poster presentation at European Hematology Association (EHA) Congress, Madrid, Spain. Abstract P922"},{"issue":"3","key":"6705_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030182","volume":"32","author":"M Ho","year":"2025","unstructured":"Ho M, Paruzzo L, Minehart J, Nabar N, Noll JH, Luo T, Garfall A, Zanwar S (2025) Extramedullary multiple myeloma: challenges and opportunities. Curr Oncol 32(3):182. https:\/\/doi.org\/10.3390\/curroncol32030182","journal-title":"Curr Oncol"},{"issue":"15","key":"6705_CR37","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1182\/bloodadvances.2025016619","volume":"9","author":"S Zanwar","year":"2025","unstructured":"Zanwar S, Novak J, Gonsalves W, Howe M, Braggio E, Rajkumar SV, Binder M, Jevremovic D, Dasari S, Kumar S (2025) Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations. Blood Adv 9(15):3979\u20133987. https:\/\/doi.org\/10.1182\/bloodadvances.2025016619","journal-title":"Blood Adv"},{"issue":"3","key":"6705_CR38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1096\/fj.06-6610com","volume":"21","author":"T Tohami","year":"2007","unstructured":"Tohami T, Drucker L, Shapiro H, Radnay J, Lishner M (2007) Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J 21(3):691\u2013699. https:\/\/doi.org\/10.1096\/fj.06-6610com","journal-title":"FASEB J"},{"issue":"1","key":"6705_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","volume":"96","author":"S Mangiacavalli","year":"2017","unstructured":"Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, Cartia CS, Cazzola M, Corso A (2017) The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol 96(1):73\u201380. https:\/\/doi.org\/10.1007\/s00277-016-2847-z","journal-title":"Ann Hematol"},{"issue":"2","key":"6705_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodr\u00edguez-Otero P, Avivi I, Quijano Card\u00e9 NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, Mateos MV (2025) Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 392(2):138\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa2406536","journal-title":"N Engl J Med"},{"issue":"9","key":"6705_CR41","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodr\u03afguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab M-S, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267. https:\/\/doi.org\/10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"issue":"6","key":"6705_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Mart\u00ednez-L\u00f3pez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"issue":"1","key":"6705_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"D Dima","year":"2024","unstructured":"Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, Mahmoudjafari Z, Williams L, Faiman B, McGuirk JP, Sauter CS, Ahmed N, Khouri J, Hashmi H (2024) Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J 14(1):90. https:\/\/doi.org\/10.1038\/s41408-024-01068-w","journal-title":"Blood Cancer J"},{"issue":"1","key":"6705_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK (2024) Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol 17(1):42. https:\/\/doi.org\/10.1186\/s13045-024-01555-4","journal-title":"J Hematol Oncol"},{"key":"6705_CR45","doi-asserted-by":"publisher","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P (2025) Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.\u00a0Lancet Haematol\u00a012(4):e269\u2013e281. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5","DOI":"10.1016\/S2352-3026(24)00385-5"},{"issue":"4","key":"6705_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) Car-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"issue":"8","key":"6705_CR47","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.ymthe.2024.05.039","volume":"32","author":"S Al Hadidi","year":"2024","unstructured":"Al Hadidi S, Heslop HE, Brenner MK, Suzuki M (2024) Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies. Mol Ther 32(8):2444\u20132460. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.039","journal-title":"Mol Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06705-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:56:57Z","timestamp":1781621817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06705-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6705"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06705-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"P.M.V. has served in a consulting or advisory role for AbbVie, Ascentage Pharma, AstraZeneca, BMS, GSK, Johnson & Johnson, Kite, Pfizer, and Regeneron; and has received research funding from AbbVie, Johnson & Johnson, and Regeneron. S.K. has received research funding from Celgene, Johnson & Johnson, Millennium, Novartis, and Sanofi. S.Z.U. has served in a consulting\/advisory role for AbbVie, Amgen, BMS\/Celgene, Celgene, Genentech, Gilead Sciences, GSK, Johnson & Johnson, Karyopharm Therapeutics, Merck, and Takeda; and has received research funding from Amgen, Array BioPharma, BMS, Celgene, GSK, Merck, Pharmacyclics, Sanofi, Seattle Genetics, and SkylineDx. J.C.Y. has served in a consulting\/advisory role for Bristol Myers Squibb, Johnson & Johnson, and Sanofi; and has received research funding from Celgene, Genmab, GlaxoSmithKline, MingSight, Novartis, Pfizer, and Regeneron. Y.C.C. has received research funding from Amgen, Karyopharm, and Takeda; and has received honoraria or served as a consultant\/advisor to Amgen, GSK, Johnson & Johnson, Neopharm\/Promedico, and Takeda. E.S. is employed by Johnson & Johnson and has stock\/other ownership interests in Johnson & Johnson. R.L.C. is employed by Johnson & Johnson and has stock\/other ownership interests in Johnson & Johnson. C.H. is employed by Johnson & Johnson and has stock\/other ownership interests in Johnson & Johnson. R.G. was employed by Johnson & Johnson at the time of this analysis and has stock\/other ownership interests in Johnson & Johnson. B.A. is employed by Johnson & Johnson and has stock\/other ownership interests in Johnson & Johnson. J.Z. is employed by Johnson & Johnson and has stock\/other ownership interests in Johnson & Johnson. E.C. is employed by Johnson & Johnson and has stock\/other ownership interests in Johnson & Johnson. T.P. is employed by Johnson & Johnson and has stock\/other ownership interests in Johnson & Johnson. M.-V.M. has served in a consulting\/advisory role for AbbVie, Amgen, Celgene, GlaxoSmithKline, Johnson & Johnson, Pfizer, Regeneron, Roche-Genentech, and Takeda; and has received honoraria from Amgen, AbbVie, Celgene, GlaxoSmithKline, Genentech, Johnson & Johnson, Sanofi, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}